




Skeletal Muscle Relaxants

Neuromuscular Junction

- 1: Cholinergic motor neurone, 2: motor end-plate, 3: vesicles, 4: $N_M R$, 5: mitochondrion





B

 Na^+


ACh

ACh

Outside

 α δ γ α β

Inside

 Na^+ 

Skeletal Muscle Relaxants


■ Neuromuscular Blockers:

- Nondepolarizing Drugs
- Depolarizing Drugs

■ Spasmolytics.

■ Directly Acting Drug.

Neuromuscular Blockers



Neuromuscular blockers

■ Non depolarizing agents

■ Isoquinoline

- Tubocurarine
- Doxacurium
- Atracurium
- Metocurine
- Mivacurium


Steriod derivatives

- Pancuronium
- Pipecuronium
- Rapacuronium
- Rocuronium
- Vecuronium


Neuromuscular Blockers

■ Chemistry:


- One or two quaternary nitrogen's, i.e. poorly lipid soluble or highly polar compounds.
- Double acetylcholine molecules linked:
 - End to end.
 - Concealed, bulky semi- rigid ring systems.



Acetylcholine



Succinylcholine



Pancuronium

Neuromuscular Blockers

■ Pharmacokinetics:

- Must be given parenterally.

- Nondepolarizing Drugs:

- Excreted in the kidney metabolized by the liver.

- Mivacurium is metabolized by cholinesterases.

- Atracurium is spontaneously broken down (HOFMAN ELIMINATION)....Laudanidine

Depolarizing agents

- Suxamethonium (Succinylcholine)
- Decamethonium

These drugs are structural analogue of acetylcholine .

These are used parentally

Neuromuscular Blockers

■ Pharmacokinetics:

– Depolarizing Drugs:

- Extremely short duration(5-10 minutes).
- Metabolized by cholinesterases in the plasma and liver.
- Only a small percentage reaches the neuromuscular junction, where it diffuse away into the extracellular fluid.
- Some patients have a genetically abnormal variant of plasma cholinesterase.
- *Dibucaine Number*: is a measure of the ability of a patient to metabolize succinylcholine.

Table 27–1. Some properties of neuromuscular blocking drugs.

Drug	Elimination	Clearance (mL/kg/min)	Approximate Duration of Action (minutes)	Approximate Potency Relative to Tubocurarine
Isoquinoline derivatives				
Atracurium	Spontaneous ¹	6.6	20–35	1.5
Cisatracurium	Mostly spontaneous	5–6	25–44	1.5
Doxacurium	Kidney	2.7	> 35	6
Metocurine	Kidney (40%)	1.2	> 35	4
Mivacurium	Plasma ChE ²	70–95	10–20	4
Tubocurarine	Kidney (40%)	2.3–2.4	> 35	1
Steroid derivatives				
Pancuronium	Kidney (80%)	1.7–1.8	> 35	6
Pipecuronium	Kidney (60%) and liver	2.5–3.0	> 35	6
Rocuronium	Liver (75–90%) and kidney	2.9	20–35	0.8
Vecuronium	Liver (75–90%) and kidney	3–5.3	20–35	6
Depolarizing agent				
Succinylcholine	Plasma ChE ² (100%)	>100	< 8	0.4

¹Nonenzymatic and enzymatic hydrolysis of ester bonds.²Butyrylcholinesterase (pseudocholinesterase).

Properties of neuromuscular blockers

Drug	Elimination via	Duration of action (minutes)
Short-acting		
Succinylcholine	Plasma AChE	5-10
Mivacurium	Plasma AChE	10-20
Intermediate-acting		
Atracurium	Spontaneous	20-35
Vecuronium	Hepatic and renal	20-35
Rocuronium	Hepatic and renal	20-35
Long-acting		
Pancuronium	Renal	60

Neuromuscular Blockers

■ Mechanism of Action


– Nondepolarizing Drugs:

- Compete with acetylcholine at the nicotinic receptor sites at the NMJ.
- In high doses, can enter the pore of the ion channel to cause a more intense blockade.
- Can also block prejunctional sodium channels to interfere with the mobilization of acetylcholine at the nerve ending.

d-Tubocurarine

CN1CC[C@H]2C=C[C@H](COC)C(=C2)C1Cc1ccc(O)c(OC)c1

Pancuronium



Blockade of ACh receptors
No depolarization of
endplate

Relaxation of skeletal muscles
(Respiratory paralysis)

Artificial
ventilation
necessary
(plus general
anesthesia!)

Antidote:
cholinesterase
inhibitors
e.g., neostigmine

Neuromuscular Blockers

■ Mechanism of Action:

– Depolarizing Drugs:

- *Phase I Block(depolarizing)*: succinylcholine reacts with nicotinic receptors to opens the channel and cause depolarization of the motor end plate which will spread to adjacent membranes, causing contractions of muscle motor units.
- Can enter the channel to produce a prolonged “flickering” of the ion conductance.
- The depolarized membranes remain depolarized and unresponsive to subsequent impulses causing paralysis which is augmented by cholinesterase inhibitors.


Neuromuscular Blockers

■ Mechanism of Action:


– Depolarizing Drugs:

- *Phase II Block(desensitizing)*: with continued exposure, depolarization decreases and the membrane becomes repolarized and can not be depolarized again because it is desensitized. This may be due to blockade of ion channel, which might be more important than the action of the agonist at the receptor, i.e. the channels behave as if they are in a prolonged closed state.
- This phase is reversed by acetylcholinesterase inhibitors.

▼ Agonist




Closed
normal




Open
normal

▼ Nondepolarizing
blocker



Closed
blocked

▼ Depolarizing
blocker




Open
blocked

Clinical use of neuromuscular blockers



- ❖ **Muscle relaxation during surgical procedures**
- ❖ **Endotracheal intubation**
- ❖ **Maintain controlled ventilation**

Clinical problems associated with neuromuscular blockers






- ❖ **Potentiated by inhaled anesthetics (Isoflurane)**
- ❖ **Potentiated by aminoglycosides and calcium channel blockers**
- ❖ **Can block autonomic ganglia at higher doses**
- ❖ **Respiratory paralysis**



Acetylcholine



Succinylcholine




A. Action of the depolarizing muscle relaxant succinylcholine

Actions of Neuromuscular Blockers

■ Skeletal Muscle Paralysis:

– Nondepolarizing Drugs:

- Onset of effect is very rapid.**
- Motor weakness followed by flaccidity.**
- Starts with small muscles, large muscles are more resistant to blockade and recover more rapidly. Diaphragm is last to be paralysed.**
- Effects lasts for 45-60 minutes.**



Actions of Neuromuscular Blockers

■ Skeletal Muscle Paralysis:

– Nondepolarizing Drugs:

– Depolarizing Drugs:

- Action starts by transient muscle fasciculations over the chest and abdomen within 30 seconds.**
- Paralysis develops rapidly (within 90 seconds), the arm, neck, and leg muscles followed by the respiratory muscles.**
- Blockade lasts less than 10 minutes.**

Actions of Neuromuscular Blockers

■ Skeletal Muscle Paralysis.

■ Cardiovascular Effects:

- Mediated by autonomic or histamine receptors.**
- Both sympathetic and parasympathetic ganglia and muscarinic receptors in the heart can be stimulated.**
- Usually cause hypotension, which can be attenuated by antihistamines.**

Actions of Neuromuscular Blockers

- **Skeletal Muscle Paralysis.**
- **Cardiovascular Effects.**
- **Hyperkalemia:**
 - In patients with burns, nerve damage, or neuromuscular disease, head injury, and other trauma.
 - Can result in cardiac arrest.

Actions of Neuromuscular Blockers

- **Skeletal Muscle Paralysis.**
- **Cardiovascular Effects.**
- **Hyperkalemia:**
- **Increased Intraocular Pressure:**
 - Due to tonic contraction of myofibrils or transient dilation of ocular choroidal blood vessels.
- **Increased Intra gastric Pressure:**
 - In obese, heavily muscled, diabetics, traumatic patients, fasciculations of succinylcholine can cause regurgitation and aspiration of gastric contents.
- **Muscle Pain:**
 - Due to unsynchronized contractions of adjacent muscle fibers just before the onset of paralysis.

Drug Interactions of Neuromuscular Blockers

■ Anesthetics:

- Mostly with isoflurane, and least with nitrous oxide.
- May be due to a central action, increased muscle blood flow.
- Can cause *Malignant Hyperthermia*.

■ Antibiotics:

- Depress release of acetylcholine due to blockade of specific P-type of calcium channels.

■ Local anesthetics and antiarrhythmic Drugs

■ Other Neuromuscular Blockers.

Spasmolytics

- **Chronic neurologic diseases**
 - **Multiple Sclerosis**
- **Acute Injury**
 - **Spinal cord damage, muscle inflammation**

Goal of therapy: Reduce spasticity and pain, while retaining function

Spasmolytic Drugs

■ Diazepam:

- Acts at GABA_A receptors in the CNS.
- Sedative.


Spasmolytic Drugs

■ Baclofen:

- Acts at GABA_B receptors, resulting in hyperpolarization and presynaptic inhibition through reducing calcium influx.
- Can also reduce spasticity by inhibiting release of substance P in the spinal cord.
- Less sedative, but can cause drowsiness.
- Can be given intrathecally.
- Can reduce craving in alcoholics and in migraine.

Spasmolytic Drugs

- **Tizanidine:**
 - Related to clonidine.
- **Gabapentin:**
 - An antiepileptic Glycine.
- **Others**



Directly Acting Drugs

■ Dantrolene:

- Related to phenytoin, an antiepileptic.
- Interferes with excitation-contraction coupling in the muscle fibers by interfering with the release of activator calcium by binding with the ryanodine receptor (RyR) channel of the sarcoplasmic reticulum.
- Useful in treatment of malignant hyperthermia

Malignant Hyperthermia

- Rare heritable disorder triggered by a variety of stimuli, including general anesthetics and neuromuscular blockers.
- Patients have a hereditary impairment of the sarcoplasmic reticulum to sequester calcium.
- The trigger can cause sudden and prolonged release of calcium, with massive contraction, lactic acidosis, and increased body temperature.
- Treatment is by cooling, correcting acidosis, and dantrolene to reduce calcium release.

Botulinum Toxin

Produced by *Botulinum* bacteria.

Inhibits acetylcholine release.

Food poisoning caused by this bacteria can result, within 12-36 hours, in diplopia, dysphagia, dysarthria, and dyspnea.

Toxin is use for opthalmic purposes, local muscle spasms, and in the cosmetic treatment of facial wrinkles around the eyes and mouth, as well as for generalized spastic disorders like cerebral palsy.